Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)

This publication has 39 references indexed in Scilit:

• Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition
  The Oncologist, 2004
• Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
  Journal of Clinical Oncology, 2002
• The EGFR family and its ligands in human cancer
  European Journal Of Cancer, 2001
• Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
  New England Journal of Medicine, 2001
• Untangling the ErbB signalling network
  Nature Reviews Molecular Cell Biology, 2001
• NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer
  The EMBO Journal, 2000
• Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
  Journal of Clinical Oncology, 1999
• ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
  The EMBO Journal, 1997
• Humanization of an anti-p185HER2 antibody for human cancer therapy.
  Proceedings of the National Academy of Sciences, 1992
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987